ArticleJGH open : an open access journal of gastroenterology and hepatology2025

Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment-Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab.

Naohiro Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.